Clinical, virological and immunological responses in Danish HIV patients receiving raltegravir as part of a salvage regimen

Figures & data

Table 1 Characteristics and demographics of patients treated with raltegravir and a control population naïve to HAART

Characteristics	Raltegravir patients N = 32	Controls N = 64
Male gender	21 (65.6%)	42 (65.6%)
Age at time of index date, median (IQR), years	50.8 (42.5–55.1)	47.3 (40.5–56.3)
Race
Caucasian	23 (71.9%)	46 (71.9%)
Black	7 (21.9%)	14 (21.9%)
Other	2 (6.2%)	4 (6.2%)
Route of HIV infection
Men who have sex with men	15 (46.9%)	30 (46.9%)
Heterosexually infected	17 (53.1%)	34 (53.1%)
Injection drug user	None	None
Other	None	None
Diagnosed with HIV before 1 January 1995	9 (28.1%)	5 (7.8%)
CD4 cell count at index date, median (IQR), cells/μL	280 (60–291)	221 (181–472)
Viral load at index date, median (IQR), log10 copies/mL	2.45 (1.60–3.16)	4.40 (3.24–5.46)
Time from HIV diagnosis to index date, median (IQR), years	15.3 (12.5–18.8)	0.2 (0.1–3.4)
Time from HAART start to index date, median (IQR), years	10.7 (10.0–11.3)	–
One or more AIDS-defining events prior to index date	14 (43.8%)	11 (17.2%)

Abbreviations: IQR, interquartile range.

Table 2 Characteristics of HAART regimens used prior to first raltegravir regimen

Number of all NRTIs, NNRTIs, and PIs used prior to first raltegravir regimen	Median (IQR)
NRTI	5 (5–7)
NNRTI	1 (1–2)
PI	4 (4–5)
Drugs included in the last HAART regimen prior to first raltegravir initiation	N (%)
NRTI	31 (96.9)
1 NRTI	2 (6.3)
2 NRTI	22 (68.8)
3 NRTI	7 (21.9)
NNRTI	4 (12.5)
PI	32 (100)
Boosted PI	28 (87.5)
Non-boosted PI	4 (12.5)

Abbreviations: IQR, interquartile range; NRTIs, nucleoside reverse transcriptase inhibitors; NNRTIs, non-nucleoside reverse transcriptase inhibitors; PIs, protease inhibitors.

Table 3 Antiretroviral drugs in first raltegravir regimen

Antiretroviral drugs	N (%)
NRTI	24 (75.0)
1 NRTI	3 (9.4)
2 NRTI	17 (53.1)
3 NRTI	4 (12.5)
NNRTI	14 (43.8)
Etravirine	12 (37.5)
Boosted PI	30 (93.8)
Darunavir	28 (87.5)
Non-boosted PI	2 (6.7)
CCR5 inhibitor (maraviroc)	3 (9.4)
Fusion inhibitor (enfuvirtide)	1 (3.1)

Abbreviations: NRTIs, nucleoside reverse transcriptase inhibitors; NNRTIs, non-nucleoside reverse transcriptase inhibitors; PIs, protease inhibitors.

Figure 1 Fraction of viral load (VL) tests below 51 copies/mL in 12 weeks intervals for the raltegravir cohort (full line) and the control cohort (broken line). Week 0 is start of raltegravir or HAART (index date).

Figure 2 Median CD4 cell count at 12-week intervals for the raltegravir cohort (full line) and the control cohort (broken line). Week 0 is start of raltegravir or HAART (index date).

Figure 3 Kaplan–Meir curve of time to change in first raltegravir-containing (full line) or HAART (broken line) regimens.

Table

Patient	Pre-raltegravir treatment	On-raltegravir treatment
#1	ZDV, 3CT, ABC, RTV, DRV	ZDV, 3CT,ABC, RTV, DRV, RAL
#2	ZDV, 3CT, RTV	FTC, TDF, DRV, NVP, ETV, RAL
#3	ZDV, 3CT, RTV	3CT, ABC, RTV, DRV, ETV, RAL
#4	TDF, RTV, EFV	RTV,DRV, ETV, RAL
#5	ZDV, TDF, ATV	FTC, TDF, ATV, RAL
#6	3CT, ABC, TDF, RTV, ATV	RTV, DRV, ETV, RAL
#7	3CT, ABC, RTV, ATV, EFV	FTC, TDF, RTV, DRV, RAL
#8	3CT, ABC, RTV, ATV	FTC, TDF, RTV, DRV, RAL
#9	RTV, LPV, EFV	FTC, TDF, RAL
#10	3CT, ABC, RTV, TPV, t20	RTV, DRV, RAL, MVC
#11	ZDV, 3CT, TDF, RTV, TPV	FTC, TDF, RTV, DRV, ETV, RAL
#12	3CT, ABC, RTV, ATV	RTV, DRV, ETV, RAL
#13	ZDV, 3CT, TDF, RTV, TPV	FTC, TDF, RTV, DRV, RAL
#14	ZDV, 3CT, ATV	ABC, TDF, DRV, RAL
#15	D4T, ABC, TDF, SQV, RTV	RTV, DRV, ETV, RAL
#16	3CT, DDI, TDF, RTV, TPV	FTC, DDI, TDF, RTV, DRV, RAL, T20
#17	3CT, ABC, RTV	TDF, RTV, RAL
#18	DDI, TDF, RTV, AMP	RTV, DRV, RAL, ETV
#19	3CT, D4T, DDI, RTV, IDV,	ZDV,3CT, ABC, RTV, ETV, RAL
#20	DDI, ABC, RTV	RTV, DRV, RAL
#21	3CT, D4T, RTV	3CT, DDI, RTV, DRV, RAL
#22	3CT, D4T, RTV	FTC, TDF, DRV, ETV, RAL
#23	DDI, ABC, RTV	DRV, EFV, ETV, RAL
#24	DDI, ABC, ATV	FTC, TDF, RTV, DRV, RAL
#25	FTC, TDF, RTV	FTC, RTV, DRV, RAL
#26	DDI, ABC, RTV, ATV	FTC, TDF, RTV, DRV, RAL
#27	ABC, RTV	3CT, ABC, RTV, DRV, RAL
#28	ZDV, TDF, SQV, RTV	ZDV, FTC, TDF, SQV, RTV, DRV, RAL, MVC
#29	ABC, TDF, RTV,	ABC, TDF, RTV, DRV, RAL
#30	ABC, TDF, RTV, TPV	3CT, ABC, RTV, DRV, ETV, RAL
#31	ZDV, 3CT, RTV, EFV	FTC, TDF, DRV, RAL, MVC
#32	ZDV, DDI, RTV, IDV	TDF, RTV, DRV, NVP, RAL

Abbreviations: TDF, tenofovir; RTV, ritonavir; SQV, saquinavir; FTC, emtricitabine; DRV, darunavir; DDI, didanosine; ABC, abacavir; 3TC, lamivudine; D4T, stavudine; LPV, lopinavir; EFV, efavirenz; TPV, tipranavir; FPV, fosamprenavir; NVP, nevirapine; ATV, atazanavir; IDV, crixivan; ZDV, zidovudine; ETV, etravirine; MVC, maraviroc; AMP, amprenavir.